- Home
- LUNG
LUNG
Pulmonx Corporation
as 06-20-2025 3:38pm EST
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 124.0M | IPO Year: | 2020 |
| Target Price: | $11.53 | AVG Volume (30 days): | 366.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $9.37 | Next Earning Date: | 07-30-2025 |
| Revenue: | $87,473,000 | Revenue Growth: | 19.84% |
| Revenue Growth (this year): | 18.02% | Revenue Growth (next year): | 18.17% |
Stock Insider Trading Activity of Pulmonx Corporation (LUNG)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Ferrari Richard | LUNG | Director | Jun 12 '25 | Sell | $3.16 | 8,000 | $25,280.00 | 87,024 | |
| Florin Daniel P | LUNG | Director | Jun 5 '25 | Buy | $3.06 | 23,321 | $71,362.26 | 117,231 | |
| Joshi Mehul | LUNG | Chief Financial Officer & PAO | Jun 2 '25 | Sell | $3.13 | 8,061 | $25,230.93 | 217,646 | |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Jun 2 '25 | Sell | $3.13 | 6,947 | $21,748.12 | 390,370 | |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Jun 2 '25 | Sell | $3.13 | 10,457 | $32,735.76 | 282,961 |
Latest Pulmonx Corporation News
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
Argus Research
15 days ago
Daily – Vickers Top Buyers & Sellers for 06/06/2025
GlobeNewswire
24 days ago
Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire
2 months ago
Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference
Thomson Reuters StreetEvents
2 months ago
Q1 2025 Pulmonx Corp Earnings Call
GuruFocus.com
2 months ago
Pulmonx Corp (LUNG) Q1 2025 Earnings Call Highlights: Strong International Growth Amid Domestic ...
Zacks
2 months ago
Pulmonx Corporation (LUNG) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
2 months ago
Pulmonx Reports First Quarter 2025 Financial Results
GlobeNewswire
2 months ago
Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025
Compare LUNG vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.